Cencora Q1 FY26 earnings call COR

Cencora's MSO expansion, including the recent acquisition of OneOncology and the one-year anniversary of RCA, is central to its strategy. These investments strengthen leadership in specialty pharmaceuticals, support market leaders, and enhance patient access. The MSO platform leverages capabilities like clinical research, revenue cycle management, and data-driven clinical insights to support physicians and advance care, creating a significant footprint for deployment.

Retina Consultants of America (RCA) has performed well, contributing to over one-third of all retina clinical trial research in the U.S. RCA physicians have adopted advanced technologies, such as imaging devices, and were leaders in the early adoption of a key retina biosimilar product, driving patient access to high-quality, lower-cost treatments. This demonstrates the value of supporting healthcare leaders at the forefront of innovation and has exceeded initial expectations.

OneOncology partner practices are active contributors at leading oncology conferences, presenting research on emerging treatments like cellular therapies and CAR-T. Their physicians play a crucial role in advancing cancer care and expanding access to complex treatments in local communities, aligning with Cencora's goal of enhancing patient access to pharmaceuticals. The platform is well-positioned and high-performing, expected to be a meaningful contributor to Cencora's operating income.

Cencora successfully navigated the initial IRA price negotiations by leveraging its strategic global sourcing team and contractual terms. The company maintained its economics and gross profit dollars despite list price reductions, demonstrating its ability to protect profitability through discussions with manufacturers. Price increases for other brands were in line with expectations, indicating effective preparation and execution.

The International Healthcare Solutions segment maintained its full-year operating income guidance despite a Q1 decline. This decline was attributed to a timing difference^📎 in manufacturer price adjustments in a developing market country, which is expected to normalize^📎. The Global Specialty Logistics business showed encouraging trends with volume growth and operating income growth, contributing to the segment's overall resilience and positioning for success as the market rebounds.

Cencora is prioritizing growth-oriented investments and assessing its business portfolio for strategic alignment. The full impairment of depreciable assets in the U.S. consulting business, which eliminated future depreciation expense, reflects progress in focusing the portfolio. This move, while small in enterprise context, aims to create management and strategic focus, potentially benefiting the long-term growth rate.